Close

Needham & Company Reiterates Sage Therapeutics (SAGE) at Buy, but Expects Stock to be Down on Day 15 Endpoint Miss

February 16, 2022 7:55 AM EST Send to a Friend
Needham & Company analyst Ami Fadia reiterated a Buy rating and $85.00 price target on Sage Therapeutics (NASDAQ: SAGE), following ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login